A Phase I/II Study to Evaluate the Safety and Efficacy of TWB-103 in Adult Patients With Split-Thickness Skin Graft Donor Site Wounds (DSW)
Phase of Trial: Phase I/II
Latest Information Update: 20 Jul 2017
At a glance
- Drugs TWB 103 (Primary)
- Indications Wounds
- Focus Adverse reactions; Therapeutic Use
- Sponsors Transwell Biotech
- 13 Jul 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Mar 2018.
- 13 Jul 2017 Status changed from not yet recruiting to recruiting.
- 08 Nov 2016 According an Elanix Biotechnologies media release, company has received IND clearance from the US FDA to conduct this trial. Patients enrolment at Taiwan and Japan location is expected by Q2 2017.